



Provision Center for Proton Therapy Begins Patient Treatments

1st patient treated 12 months after the start of installation, increasing US proton therapy treatment capacity.

Knoxville, TN, USA, January 24, 2014 - The Provision Center for Proton Therapy and IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announced today that Provision Center for Proton Therapy in Knoxville, TN, USA has begun proton therapy treatments on January 20, 2014.

Offering advanced radiation therapy to patients in the Southeast region, (*ie.* the latest proton beam technology developed by Belgium-based IBA), will benefit adult and pediatric cancer patients who are seeking advanced cancer care with lower treatment-related side effects and a better quality of life during and after treatment.

With the first patient treatments beginning in Knoxville 12 months after the start of installation of the proton equipment on-site, IBA could break records of installation time thanks to the unique expertise of its experts and engineers. Installations after installations, IBA continues to reduce the time to equip proton therapy centers and prepare them to treat patients. Such assurance helps medical institutions reduce their technological and financial risk.

IBA will now focus on delivering the two remaining Gantry Treatment rooms that include IBA Pencil Beam Scanning (PBS). Once completed, Provision Center for Proton Therapy will be the latest of multiple IBA centers treating cancer patients with Pencil Beam Scanning, the most precise form of Proton Therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.

Bill Hansen, VP of Strategic Development at Provision Center for Proton Therapy, commented: "Provision and IBA are demonstrating that a strong partnership can help bring advanced cancer care to our community on schedule. We look forward to growing the treatment capacity in the coming weeks. The whole Provision team is eager to bring this extraordinary cancer treatment to East Tennessee and the entire Southeast Region."

Olivier Legrain, IBA CEO added: There is urgency to open more proton centers around the world, to make this extraordinary cancer care modality accessible to more patients. Recent reports show that proton therapy would be beneficial for up to 20% of the patients treated with conventional radiation therapy. That represents thousands of patients in the Southeast region. I am really pleased that ambitious healthcare entrepreneurs such as Provision trusted IBA to bring proton therapy to their hometown in Tennessee. This partnership reflects the confidence that our customers have in us and reinforces IBA's position as the undisputed leader in proton therapy worldwide"

Beth Klein, IBA VP Sales North America, shared: "We are very pleased with the addition of the Provision Center for PT to the growth of the treatment capacity in proton therapy in the USA. To date, IBA has helped its clinical partners treat more than 25,000 cancer patients, with 5,000 of those patients treated in 2013 alone. The growth in treatment capacity of the IBA installed base is exponential, thanks to our customer's confidence in selecting IBA as their secure partner. We are proud to make this extraordinary and powerful treatment ever more accessible to patients."

-----END-----



About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. www.iba-protontherapy.com

Today, more than half of proton therapy clinical facilities worldwide are IBA systems. This includes 16 proton therapy centers in operation and 10 additional centers under development. Over 25,000 patients have been treated on IBA equipment – more than on all major competitive installations combined.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Provision Center for Proton Therapy

The [Provision Center for Proton Therapy](#) is the first of its kind in Tennessee and only the second in the Southeast. The center provides one of the most advanced cancer treatments in the world to patients in the region. Open to all credentialed physicians and health systems in the region, the Provision Center for Proton Therapy will have three treatment rooms and will be able to treat up to 1,000 cancer patients annually, and will bring in many patients from outside the area. The center brings to Knoxville an advanced cancer treatment capability that presently is available in only a handful of cities in the U.S. It is one of only 14 operating proton centers in the nation.



For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager PT
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal
+44 (0) 207 920 2333
IBA@consilium-comms.com

Provision Center for Proton Therapy

Gretchen Crawley
Marketing Manager
(865) 321-4554
gretchen.crawley@provisionhp.com

Bill Hansen
VP of Strategic Development
(865) 321-4568
bill.hansen@provisionproton.com